# SPR

> SPR is the Cleveland medical-device company behind the SPRINT PNS System, a prescription therapy that places a fine lead near a peripheral nerve, delivers mild electrical stimulation for up to 60 days, and then removes the hardware rather than leaving a permanent implant. Founder Maria Bennett traced the idea to an unexpected pain result in graduate-school research, built a commercial company around clinical evidence and reimbursement, reached 50,000 implants by December 2025, and completed a $650 million cash sale to Medtronic in July 2026.

- **Founded:** 2010
- **Headquarters:** Cleveland, United States
- **Founders:** Maria E. Bennett (President, CEO and Founder)
- **Team size:** More than 300 employees were publicly reported in early 2026; supplied company data estimates approximately 430. Offices were reported in Cleveland, Chapel Hill and the Minneapolis area before the Medtronic integration.
- **Products:** SPRINT PNS System, SPRINT endura, SPRINT extensa, SPRINT extensa XT, SPRcare Patient Access Program
- **Notable:** First-generation SPRINT PNS received FDA 510(k) clearance in 2016., Commercial launch followed in 2017, reaching 1,000 patients in 2019 and 5,000 by May 2021., Expanded FDA clearance in 2021 broadened treatable anatomical areas beyond the original back and extremity indication.

## Products & services

- **SPRINT PNS System** — FDA-cleared prescription system for up to 60 days of percutaneous peripheral nerve stimulation for indicated acute and chronic pain; the temporary MicroLead is removed after treatment.
- **SPRINT endura** — Single-lead configuration with an external wearable pulse generator and patient-controlled stimulation.
- **SPRINT extensa** — Dual-lead configuration that can stimulate two locations.
- **SPRINT extensa XT** — Dual-lead configuration incorporating Bimodal PNS treatment.
- **SPRcare Patient Access Program** — Coverage, reimbursement and appeals support for providers and eligible patients navigating access to PNS treatment.
- **SPRINT PNS Patient App** — iOS and Android education, setup guidance and troubleshooting support for patients using the system.

## Achievements

- First-generation SPRINT PNS received FDA 510(k) clearance in 2016.
- Commercial launch followed in 2017, reaching 1,000 patients in 2019 and 5,000 by May 2021.
- Expanded FDA clearance in 2021 broadened treatable anatomical areas beyond the original back and extremity indication.
- Reached 30,000 treated patients in July 2024 and 50,000 implants in December 2025.
- A 2024 CMS hospital outpatient rule recognized SPRINT as an eligible non-opioid treatment for separate payment under qualifying circumstances.
- Reported five consecutive Top Workplaces awards and a second consecutive USA TODAY Top Workplaces recognition in 2026.
- Medtronic completed its $650 million cash acquisition of SPR on July 16, 2026.

## Latest updates

- **2025-12** — SPR announced its 50,000th SPRINT PNS implant, up from 30,000 in July 2024.
- **2026-04** — SPR received a second consecutive USA TODAY Top Workplaces award, based on employee survey feedback.
- **2026-05** — Medtronic agreed to acquire SPR for approximately $650 million in upfront cash.
- **2026-07** — SPR reported five-plus-year follow-up data among prior low-back-pain responders; 79% of 602 survey participants avoided subsequent invasive interventions during follow-up.
- **2026-07** — Medtronic completed the $650 million acquisition and integrated SPR into Medtronic Pain Interventions.

## Links

- Website: https://sprpainrelief.com
- LinkedIn: https://www.linkedin.com/company/spr-pain-relief
- Twitter/X: https://twitter.com/sprintpns
- Facebook: https://www.facebook.com/sprintpns

---

Profile page: https://yespress.io/spr
Published by YesPress — https://yespress.io
Last updated: 2026-08-22